Exagen (XGN) Expected to Announce Earnings on Tuesday

Exagen (NASDAQ:XGN) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Exagen to post earnings of ($0.27) per share and revenue of $13.85 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Exagen Stock Up 3.2 %

NASDAQ XGN opened at $3.23 on Friday. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. The company has a fifty day moving average of $3.83 and a two-hundred day moving average of $3.57. The firm has a market capitalization of $56.97 million, a price-to-earnings ratio of -3.44 and a beta of 1.40. Exagen has a 52 week low of $1.30 and a 52 week high of $6.22.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on XGN. William Blair reissued an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 target price on shares of Exagen in a research note on Monday, January 13th. Finally, Canaccord Genuity Group boosted their target price on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).